Patents by Inventor Jason Daniel Speake

Jason Daniel Speake has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIPARASITIC COMPOUNDS
    Publication number: 20170202849
    Abstract: The invention relates to 1,2,4-thiadiazole derivatives and their use to treat parasites.
    Type: Application
    Filed: April 3, 2017
    Publication date: July 20, 2017
    Inventors: Hao LIU, Jessica Marie Sligar, Jason Daniel Speake, Joseph A. Moore, III, Brent Christopher Beck
  • Antiparasitic compounds
    Patent number: 9643963
    Abstract: The invention relates to 1,2,4-thiadiazole derivatives and their use to treat parasites.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: May 9, 2017
    Assignee: Avista Pharma Solutions, Inc.
    Inventors: Hao Liu, Jessica Marie Sligar, Jason Daniel Speake, Joseph A. Moore, III, Brent Christopher Beck
  • ANTIPARASITIC COMPOUNDS
    Publication number: 20160280700
    Abstract: The invention relates to 1,2,4-thiadiazole derivatives and their use to treat parasites.
    Type: Application
    Filed: November 14, 2014
    Publication date: September 29, 2016
    Inventors: Hao LIU, Jessica Marie SLIGAR, Jason Daniel SPEAKE, Joseph A. MOORE, III, Brent Christopher BECK
  • Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors
    Publication number: 20140323487
    Abstract: Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
    Type: Application
    Filed: July 8, 2014
    Publication date: October 30, 2014
    Inventors: David John Cowan, Andrew Lamont Larkin, Cunyu Zhang, David Lee Musso, Gary Martin Green, Rodolfo Cadilla, Paul Kenneth Spearing, Michael Joseph Bishop, Jason Daniel Speake
  • Compounds as antagonists or inverse agonists of opioid receptors for treatment of addiction
    Patent number: 8822518
    Abstract: Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: September 2, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: David John Cowan, Andrew Lamont Larkin, Cunyu Zhang, David Lee Musso, Gary Martin Green, Rodolfo Cadilla, Paul Kenneth Spearing, Michael Joseph Bishop, Jason Daniel Speake
  • Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors
    Publication number: 20140100255
    Abstract: Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
    Type: Application
    Filed: December 12, 2013
    Publication date: April 10, 2014
    Applicant: GlaxoSmithKline LLC
    Inventors: David John Cowan, Andrew Lamont Larkin, Cunyu ZHANG, David Lee Musso, Gary Martin Green, Rodolfo Cadilla, Paul Kenneth Spearing, Michael Joseph Bishop, Jason Daniel Speake
  • Compounds as antagonists or inverse agonists at opioid receptors
    Patent number: 8633175
    Abstract: Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
    Type: Grant
    Filed: August 8, 2007
    Date of Patent: January 21, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: David John Cowan, Andrew Lamont Larkin, Cunyu Zhang, David Lee Musso, Gary Martin Green, Rodolfo Cadilla, Paul Kenneth Spearing, Michael Joseph Bishop, Jason Daniel Speake
  • AMIDES OF DIAZABICYCLOOCTANES AND USES THEREOF
    Publication number: 20110263629
    Abstract: The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS).
    Type: Application
    Filed: September 2, 2009
    Publication date: October 27, 2011
    Applicant: Targacept, Inc.
    Inventors: Jon-Paul Strachan, Balwinder Singh Bhatti, Anatoly Mazurov, Jozef Klucik, Yunde Xiao, Philip S. Hammond, David Kombo, Lan Miao, Jason Daniel Speake, Daniel Yohannes
  • NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS
    Publication number: 20110124559
    Abstract: Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
    Type: Application
    Filed: August 8, 2007
    Publication date: May 26, 2011
    Applicant: Smithkline Beecham Corporation
    Inventors: David John Cowan, Andrew Lamont Larkin, Cunyu Zhang, David Lee Musso, Gary Martin Green, Rodolfo Cadilla, Paul Kenneth Spearing, Michael Joseph Bishop, Jason Daniel Speake
  • Heterocycle compounds
    Patent number: 7939528
    Abstract: The present invention relates to novel compounds which are antagonist or inverse agonists at an opioid receptor. Such compounds are useful in the treatment of obesity and related diseases and/or conditions in mammals, particularly humans. Methods of making and using such compounds are also disclosed.
    Type: Grant
    Filed: October 12, 2006
    Date of Patent: May 10, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Kevin Karl Barvian, Jason Daniel Speake, David John Cowan, Andrew Lamont Larkin, Jerzy Ryszard Szewczyk
  • NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS
    Publication number: 20100222345
    Abstract: This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.
    Type: Application
    Filed: August 8, 2007
    Publication date: September 2, 2010
    Inventors: Caroline Jean Diaz, Curt Dale Haffner, Jason Daniel Speake, Cunyu Zhang, Wendy Yoon Mills, Paul Kenneth Spearing, David John Cowan, Gary Martin Green
  • NOVEL HETEROCYCLE COMPOUNDS
    Publication number: 20090054431
    Abstract: The present invention relates to novel compounds which are antagonist or inverse agonists at an opioid receptor. Such compounds are useful in the treatment of obesity and related diseases and/or conditions in mammals, particularly humans. Methods of making and using such compounds are also disclosed.
    Type: Application
    Filed: October 12, 2006
    Publication date: February 26, 2009
    Inventors: Kevin Karl Barvian, Jason Daniel Speake, David John Cowan, Andrew Lamont Larkin, Jerzy Ryszard Szewczyk
  • Diazepine compounds as ligands of the melanocortin 1 and/or 4 receptors
    Patent number: 7442693
    Abstract: There is provided novel diazepines that function as agonists at the melanocortin 4 receptor and as agonists at the melanocortin 1 receptor, pharmaceutical compositions containing them, methods for their use in treatment, and processes for their preparation.
    Type: Grant
    Filed: May 27, 2005
    Date of Patent: October 28, 2008
    Assignee: SmithKline Beecham Corporation
    Inventors: Jerzy Ryszard Szewczyk, Jason Daniel Speake, Douglas McCord Sammond, Ronald George Sherrill